🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million instances per year. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

As per results published in a major medical journal, the new drug cured more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which combines two antibiotics. The trial involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have expressed optimism. Having a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is deemed crucial to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.